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Background: Troponin I (TNNI3) is the inhibitory subunit of the thin filament regulatory complex Troponin,
which confers calcium-sensitivity to striated muscle actomyosin ATPase activity. Mutations (2-7%) in this gene had
been reported in hypertrophic cardiomyopathy patients (HCM). However, the frequencies of mutations and
associated clinical presentation have not been established in cardiomyopathy patients of Indian origin, hence we
have undertaken this study.
Methods: We have sequenced all the exons, including the exon-intron boundaries of TNNI3 gene in 101
hypertrophic cardiomyopathy patients (HCM), along with 160 healthy controls, inhabited in the same geographical
region of southern India.
Results: Our study revealed a total of 16 mutations. Interestingly, we have observed Arginine to Glutamine (R to Q)
mutation at 3 positions 98, 141 and 162, exclusively in HCM patients with family history of sudden cardiac death.
The novel R98Q was observed in a severe hypertrophic obstructive cardiomyopathy patient (HOCM). The R141Q
mutation was observed in two familial cases of severe asymmetric septal hypertrophy (ASH++). The R162Q
mutation was observed in a ASH++ patient with mean septal thickness of 29 mm, and have also consists of allelic
heterogeneity by means of having one more synonymous (E179E) mutation at g.4797: G!A: in the same exon 7,
which replaces a very frequent codon (GAG: 85%) with a rare codon (GAA: 14%). Screening for R162Q mutation in
all the available family members revealed its presence in 9 individuals, including 7 with allelic heterogeneity (R162Q
and E179E) of which 4 were severely affected. We also found 2 novel SNPs, (g.2653; G!A and g.4003 C! T)
exclusively in HCM, and in silico analysis of these SNPs have predicted to cause defect in recognition/binding sites
for proteins responsible for proper splicing.
Conclusion: Our study has provided valuable information regarding the prevalence of TNNI3 mutations in
Indian HCM patients and its risk assessment, these will help in genetic counseling and to adopt appropriate
treatment strategies.
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Table 1 Clinical features exhibited by hypertrophic
cardiomyopathy (HCM) patients
Baseline characteristics (n = 101)
Age, years 49 ± 10
Sex, males,% 62




LVESD, mm 20.3 ± 3.7
LVEDD, mm 36± 6.8
Septum, mm 21.2 ± 4.2
Abnormal ECG,% 62
Family history of HCM,% 37
Family history of SCD,% 32
Left ventricular outflow obstruction 49
NYHA - New York Heart Association; LVESD - Left ventricular end
systolic dimension; LVEDD - Left ventricular end diastolic dimension;
ECG - Electrocardiogram; HCM - Hypertrophic cardiomyopathy; SCD – Sudden
cardiac death.
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Inherited cardiomyopathy is a disorder of ‘cardiac
muscle’ associated with abnormalities of cardiac wall
thickness, chamber size, contraction, relaxation, conduc-
tion and rhythm, were found to be the major cause of
heart failure. It is also different from other heart disease,
as it frequently affects all the age groups, including
young children, adults and competitive athletes [1]. Over
the last two decades, a large number of mutations have
been identified in sarcomeric genes as a cause of hyper-
trophic and dilated cardiomyopathy. The sarcomere
composed of thick and thin filaments, the thick filament
is constituted mainly of myosin, and the thin filament is
composed of actin, tropomyosin and troponin complex.
Cardiac troponin I (TNNI3), the inhibitory sub-unit of
troponin complex, is 6.2 kb in size and comprised of 8
exons that encode for 210 amino acids, prevents the
contraction of muscle in the absence of calcium and
troponin C, and expressed exclusively in cardiac tissue
[2]. Troponin I has three binding sites, one for troponin T
(residue 61-112), another for troponin C (residue 113-164)
and the third one for actin-tropomyosin (residue 130-148;
173-181) of the thin filaments [3]. During the functioning
of the contractile apparatus depolarization of muscle leads
to intracellular release of calcium, which binds with tropo-
nin C. A conformational change occurs in troponin-
tropomyosin complex in such a way that actin molecules
can interact with myosin, resulting in muscle contraction.
Several mutations leading to familial hypertrophic car-
diomyopathy (FHC) have been identified in this gene
[4-6]. Analysis of cardiac beta myosin heavy chain
(MYH7) and myosin binding protein C (MyBPC3) in
Indian HCM and DCM patients revealed few genetic
variants associated with the disease [7,8]. Since the
Indian populations are culturally and geographically
highly heterogeneous; genetically we expected that
they might exhibit unique set of mutations. As there
is no comprehensive study on Indian population, we
have analysed all the exons and the exon-intron
boundries of TNNI3 gene of Indian cardiomyopathy
patients to assign its role in the etiology of cardiomy-
opathy among Indian populations.
Results
Screening of all the exons including the exon-intron
boundaries of the TNNI3 gene in 101 individuals with
HCM (Table 1) along with 160 healthy controls from
India revealed a total of 16 mutations, including 15
SNPs, and a 4 bp deletion/insertion polymorphism
(Table 2). Of the 15 SNPs, 7 were exonic (one novel, 3
reported non-synonymous and 3 synonymous muta-
tions), and 9 were intronic mutations (Table 2). Interest-
ingly, we found three heterozygous arginine to
glutamine (R to Q) substitution at 3 positions 98, 141and 162 in TNNI3 Figure 1A, 1B, 1C, of these R98Q in
exon 6 of TNNI3 gene is novel (Figure 1A) observed in a
28 years old severe hypertrophic obstructive cardiomy-
opathy patient (HOCM) with interventricular septum
(IVS) thickness of 25 mm and his 5 years old asymptom-
atic son, with the family history of sudden cardiac deaths
(Figure 2). The dominant R141Q mutation in exon 7 of
TNNI3 gene (Figure 1B), lies within the “minimum in-
hibitory sequence” (residues 137 to 148) region, was
observed in two individuals with severe familial asym-
metric septal hypertrophy (ASH+), with interventricular
septum (IVS) thickness of 25 and 28 mm, respectively.
The dominant R162Q mutation (Figure 1C) in exon 7 of
TNNI3 gene was observed in an individual with severe
asymmetric septal hypertrophy (ASH) with mean thick-
ness of 29 mm had abnormal echocardiogram/ECG.
Screening for this mutation (R162Q) in all the available
family members (Figure 3) revealed its presence in 9
individuals (Figure 1C). Seven out of 9 individuals with
R162Q mutation showed allelic heterogeneity with hav-
ing a synonymous mutation at g.4797: G!A: E179E
(Figure 1F) in exon 7, which replaces a very frequent
codon (GAG: 85%) with rare codon (GAA: 14%)
(Table 3). Four out of 7 Individuals with allelic hetero-
geneity (R162Q and E179E) (Figure 1C, 1F) had pre-
sented with severe septal hypertrophy (ASH++) with the
mean thickness of 27, 28, 29, 32 mm and the ECGs were
abnormal in all the four individuals. History of sudden
cardiac death was also been recorded in this family
(Figure 3).
C!T transition resulting in the replacement of pro-
line with arginine (P82R) in exon 5, lies within the
Table 2 Mutations observed in troponin I (TNNI3) gene of the cases/controls




1 g.1389 Intron 1 — (T/C) Nil 2 rs11667847
2 g.1403 Intron 1 — (A1/G) Nil 1 rs11671293
3 g.1215 Intron 1 C/A Nil 1 rs3729707
4 g.1486-90 Intron 1 4b p del/In ACAG P P poly
5 g.1698 Intron 2 — (T/C) Nil 4 rs3729836
6 g.1810 Intron 3 — (G/A) Nil 3 rs3729837
7 g.1897 Intron 3 — (G/A) Nil 22 rs3729838
8 g.2560 Exon 5 R68R (G/T) Nil 4 rs3729711
9 g.2563 Exon 5 R69R (C/A) Nil 2 Reported
10 g.2601 Exon 5 P82R (C/G) 1 2 Reported
11 g.2653 Intron 5 — (G/A) Nil 1 Novel
12 g.4003 Intron 6 — (C/T) Nil 2 Novel
13 g.4019 Exon 6 R98Q G/A) Nil +1(S) Novel
14 g.4682 Exon 7 R141Q (G/A) Nil 2 Reported to be associated with HCM
15 g.4745 Exon 7 R162Q (G/A) Nil 1+8 (FM) Reported to be associated with HCM
16 g.4797 Exon 7 E179E (G/A) Nil 1+6 (FM) rs3729841
AA- Amino acid, HCM-Hypertrophic cardiomyopathy, P-Polymorphic, SNP-Single nucleotide polymorphism, Nil- No mutation observed, S-Son, FM-family members.
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2 HCM patients and a control individual. A total of
three synonymous mutations (g.2560; G >T; g.2563;
C >A; g.4797; G >A) were observed exclusively in HCM
patients (Tables 2, 3). The G!T mutation at g.2560
(R68R), observed in 4 HCM patients, replaces a frequent
codon (CGG: 24%) with a less frequent one (CGT: 4%)
(Table 3). The C!A mutation at g.2563 (R69R),
observed in 2 HCM patients, replaces the frequentFigure 1 (A - F). Sequence electropherograms of TNNI3 gene. Upper p
showing the mutations observed in the HCM patients. The mutations sites
the nucleotide position g.4019 (G >A) that changes the amino acid Arginin
mutation at the nucleotide position g.4682 (G>A) that changes the amino
heterozygous mutation at the nucleotide position g.4745 (G >A) that chan
D. A novel homozygous splice acceptor site SNP at the nucleotide position
position g.4003 (TT) in Intron 6. F. A heterozygous silent mutation (E179E),codon (CGC: 36%) with rare codon (CGA: 12%) (Table 3).
The 4 bp deletion/insertion polymorphism in TNNI3
gene was observed almost in equal frequency in both the
patients and the controls, suggesting that it was not asso-
ciated with HCM.
In silico analysis of 2 novel SNPs using Splicing Rain-
bow tool predicted abnormal splicing pattern (Table 4)
by removing or creating binding sites for hnRNPs or the
SR proteins (http://www.ebi.ac.uk/asd-srv/wb.cgi?method).anel representing the control sequences, whereas the lower panel
are shown with arrows. A. Novel missense heterozygous mutation at
e (CGA) to Glutamine (CAA) at the residue 98. B. A heterozygous
acid Arginine (CGG) to Glutamine (CAG) at residue 141. C. A
ges the amino acid Arginine (CGG) to Glutamine (CAG) at residue 162.
g.2653 (AA) in intron 5. E. A novel homozygous SNP at the nucleotide
at the nucleotide position g.4797 (G >A) in exon 7.
Figure 2 A pedigree of a hypertrophic cardiomyopathy (HCM) family with R98Q mutation in the exon 6 of cardiac troponin I TNNI3
gene is depicted.
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(Table 4; Figure 1D), was found exclusively in a HCM
patient, had been predicted to abort a binding site for
hnRNP.U1U2 and one more novel mutation at g.4003
C!T (Table 4; Figure 1E), was observed exclusively
in the two severe HCM patients, revealed a drastic
change in the binding sites for hnRNPs and SR proteins
(2 sites in hnRNPs and 3 sites in SR proteins). The
disturbed binding sites due to g.4003 C!T mutation
were hnRNP-E1E2, hnRNP-I1I2, SRp20, SC35, U2AF65
(Table 4; Figure 1E), further emphasize its regulatory
role, however it needs further investigation. In addition
to the novel mutations, we have also observed SNPs
reported elsewhere; rs11667847, rs3729836, rs3729837,
rs11671293, rs3729838, rs3729711, rs3729841. The allele
frequencies of the SNPs were comparable to the Hap-
Map populations (www.HapMap.org).
Our concern is that the difference in frequencies of
the alleles observed between the cases and controls are
associated with disease or a difference unrelated to dis-
ease arising from underlying genetic differences between
the populations from which the case and control sam-
ples were drawn: ‘population stratification’. In order to
maximize our chances detecting such stratification, weFigure 3 A pedigree of a four-generation hypertrophic cardiomyopat
of cardiac (TNNI3) Troponin I gene.genotyped cases and control samples using a panel of 50
ancestry-informative markers (AIMs) for inferring ances-
try [7] and performed a principal components analysis
on the data together with HapMap samples of Chinese,
European, Yoruban [9], and found no significant differ-
ence in ancestry between cases and controls (Figure 3).
On the other hand, the Chinese, European, Yoruban, the
cases/controls were making clusters among themselves,
confirming that the 50 AIMs are sufficient for detecting
whether or not ancestry differences along this axis are
present. Thus, the population stratification along the
axis was ruled out as the cause of the disease
association.
Discussion
About 2–7% mutations in TNNI3 have been reported to
be associated with hypertrophic cardiomyopathy patients
from various populations [3,10]. As the data are often
population specific, we investigated the prevalence of
TNNI3 mutations in 101 hypertrophic cardiomyopathy
patients from southern India. We have identified R!Q
mutation at 3 positions (R98Q, R141Q, R162Q)
(Figure 1A, 1B, 1C), of which a novel R98Q missense
mutation was identified exclusively in a HOCM patienthy (HCM) family with R162Q and E179E mutations in the exon 7
Table 3 The codon usage in human cTnI (GenBank No. NM_000363) gene
Nt. Site SNP Reference Loction Nt. change Codon Site Type Codons aa fraction frequency codon usage
g.2560 rs3729711 Exon 5 G/T 68 Wild CGG (R) 0.24 28.436 6
Mutant CGT (R) 0.04 4.739 1
g.2563 Novel Exon 5 C/A 69 Wild CGC (R) 0.36 42.654 9
Mutant CGA (R) 0.12 14.218 3
g.4797 rs3729841 Exon 7 G/A 179 Wild GAG (E) 0.857 85.308 10
Mutant GAA (E) 0.143 14.218 3
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tion was present at a functionally significant domain that
lies within the Troponin T binding domain (61-112)
(Figure 1A), and was identified in a 28 year old proband
and his 5 year old asymptomatic son. There were 3 pre-
mature sudden deaths (Grand father, mother and brother)
in the family (Figure 2), suggesting that the R98Q substi-
tution is significantly associated with an adverse pheno-
type. The R141Q, R162Q mutations (Figure 1B, 1C)
reported to be associated with HCM in large tertiary
referral center population [11] were also observed in our
study. Both these mutations (R141Q, R162Q) were located
in the carboxy terminal part of troponin I and the first
binding site for troponin C domain and changes the net
charge from +1 to 0. All the three R!Q mutations at 98,
141 and 162 were exclusively observed in the hypertrophic
cardiomyopathy patients, these regions were reported to be
the functionally significant domains. A dominant R141Q
was observed in two HCM (2%) patients, (Figure 1B).
Screening of dominant R162Q and E179E mutations in
exon 7 of TNNI3 gene with the available family members
revealed the presence of R162Q mutation in 9 individuals
and the allelic heterogeneity (R162Q and E179E) in 7 out
of 9 individuals (Figure 1C, 1F). It is known that the
non-random use of synonymous codons creates codon
usage bias [12], and the translational speed and co-
translational folding are the main factors that affect
the correlation between synonymous codon usage and
protein structure [13,14]. Though the significance of
synonymous codon is still debatable, the 7 out of 9
individuals, who showed allelic heterogeneity (R162QTable 4 The hn RNPs and SR proteins binding site sequences
Rainbow” tool
S:NO SNP LOCATION Splicing Rain
Normal
1 g.2653:G > A Intron 5 GGATGCGAG




(No site)and E172E), four (out of 7) were affected more se-
verely in the family (Figure 3) therefore the role of
second synonymous mutation (E172E) (Figure 1F)
could not be ignored.
Interestingly, two novel SNPs, one at the nt position
g.2653; G!A and another one at the nt position g.4003
C!T, which were exclusively present in cases, were
estimated using Splicing Rainbow tool (http://www.ebi.
ac.uk/asd-srv/wb.cgi?method). In our study a splice
acceptor site mutation at g.2653; G!A was found to
remove a binding site for hnRNP.U1U2 and disturb the
splicing (Table 4; Figure 1D). The g.4003 C!T muta-
tion had revealed drastic changes at the binding sites
for hnRNPs and SR proteins (hnRNP-E1E2, hnRNP-I1I2,
SRp20, SC35, U2AF65), (Table 3; Figure 1E), thus pre-
dicted to disturb the splicing significantly. It has already
been suggested that the alignment of the sequences
present in the vicinity of the splice junctions has led to
consensus sequences for both the splice donor and
splice acceptor sites [15,16]. A panel of 50 ancestry-
informative markers (AIMs) [6] for inferring ancestry
was used and performed a principal components analysis
on the data together with HapMap samples [9] had
ruled out that these allelic differences between the cases
and the controls was the cause of the disease association
(Figure 4).
The frequencies of observed polymorphism in the
present study were also comparable with HapMap popu-
lations. The high prevalence of R!Q mutations (4%) at
three positions (R98Q, R141Q, R162Q) and the absence
of remaining reported mutations observed in otherin normal and mutant as predicted by “Splicing
bow & the binding site sequences
Mutant
G hnRNP.U1U2 (Site destroyed)
hnRNP.E1E2 (Site destroyed)
hnRNP.I1 I2 CCACGTTCCTCTTCCAG (New site)
SRp20 CCTCTTCCA
SC 35 (Site destroyed)
U2AF65 TCTT (New site)
Figure 4 Principal components analysis of Indian case/control samples together with Chinese, African and European HapMap samples,
based on a panel of 50 ancestry-informative SNP markers (AIMs).
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origin of Indian populations. These mutations (R98Q,
R141Q and R162Q) can be used as markers for screen-
ing HCMs in this region. However, this study needs to
be extended to know true spectrum and the prevalence
of mutations present in the remaining part of the India.
Conclusion
We have identified three R!Q mutations (R98Q,
R141Q, R162Q) accounting for about 4% of HCM, of
these R98Q was novel. Interestingly, two more novel
SNPs, predicted to disturb the splicing significantly were
also been identified in this study. Principal components
analysis of the data generated by a panel of 50 ancestry-
informative markers (AIMs) [6] with cases and controls
for inferring ancestry together with HapMap samples
had ruled out that the mutations (R98Q, R141Q, R162Q
and the 2 novel SNPs (g.2653; G!A and g.4003 C!T)
observed in the HCM patients was the cause of the dis-
ease association. The overall findings have provided
valuable information for risk assessment, genetic coun-
seling and adopt treatment strategies for hypertrophic
cardiomyopathy among Indian patients.
Methods
Ethical statement
All of the DNA samples analyzed in the present study
were derived from blood samples that were collected
with the informed written consent of the donors.
The Institutional Ethics Committee of Care Hospitals,
Hyderabad and the Centre for Cellular and MolecularBiology (CSIR), Hyderabad, India, have approved the
study. This study conforms to the principles outlined in
the Declaration of Helsinki (WMA World Medical
Association Declaration of Helsinki). The study subjects
were all South Indian patients with HCM, diagnosed
based on the NYHA (The Criteria Committee of
the New York Heart Association, 1994), WHO (www.
who.int/cardiovascular_diseases) guidelines for HCM;
the same was applied as appropriate to rule out HCM.
Case and control samples
Blood (about 10.0 ml) samples were collected from 101
hypertrophic cardiomyopathy patients from South India
(Table 1, Additional file 1: Table S1). The patients under-
went physical/clinical examinations, such as; 12 lead
ECGs, and trans-thoracic two-dimensional echocardiog-
raphy, and Doppler studies (Table 1, Additional file 1:
Table S1). One hundred and sixty healthy individuals
from the same ethnic background, without hypertension
and cardiomyopathy, based on the electrocardiograph
and echocardiograph measurements, were also recruited
for the study as controls.
DNA isolation
DNA was isolated from the blood samples using the fol-
lowing protocol: Erythrocytes were lysed with 15.0 ml of
erythrocyte lysis buffer (10 mm Tris pH 8.0, 320 M su-
crose, 5 M MgCl2, 1% Triton X-100; Sigma Chemical
Company, St Louis, MO, USA) for 5 min. After
complete lysis of erythrocytes, leucocytes were pelleted
by centrifugation at 500 g for 5 min. The leucocyte pellet
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(400 mM Tris, 60 mM EDTA, 150 M NaCl, and 1%
SDS; Sigma) and mixed thoroughly. To this, 2.0 ml
of 5.0 M sodium perchlorate (E. Merck, Darmstadt,
Germany) was added and mixed thoroughly for 2–3 min.
DNA was precipitated with absolute alcohol after extract-
ing once with phenol:chloroform (1 : 1) and once with
chloroform. DNA was washed once with 70%
ethanol and dissolved in TE buffer (10 mM Tris pH
8.0, 1 mM EDTA).
Genetic analysis
Primer sequences covering the exons, exon-intron
boundaries of TNNI3 gene, were obtained from the
website (http://genepath.med.harvard.edu/~seidman/cg3/
genes/TNNI3exons.html). Primers were synthesized using
an ABI 392 oligo synthesizer (Perkin–Elmer, Foster City,
CA, USA), and the PCRs (polymerase chain reactions)
were carried out under standard conditions, containing
50 ng of genomic DNA, 5 pM of each primer, 200 mM
dNTPs, 10X PCR buffer containing 1.5 mM MgCl2, and
1 unit of AmpliTaq Gold (Perkin–Elmer). Amplifica-
tion was carried out in a thermal cycler (MJ Research,
Waltham, MA, USA) using the following cycling
conditions: 94°C for 5 min, 35 cycles at 94°C for 1 min,
55–60°C for 1 min and 72°C for 1 min, followed by
a final extension at 72°C for 10 min. Amplicons
were purified by treating them with ExoSAP-IT, [com-
posed of Exonuclease 1 and Shrimp alkaline phosphatase
(USB Corporation, 26, 111 Miles Road, Cleveland, Ohio
44128, USA)], according to the manufacturer’s instruc-
tions. The purified PCR products were bi-directionally
sequenced using the ABI BigDye Terminator cycle se-
quencing kit (Perkin–Elmer, Foster City, CA, USA) and
analyzed using on ABI 3730 DNA Analyzer (Applied
Biosystems, Foster City, CA, USA) [17]. Sequences were
edited and compared with the reference sequence
(TNNI3) using AutoAssembler software (Applied Biosys-
tems, Foster City, CA, USA).
Sequenom iPLEX assay
We genotyped case/control samples for 50 Ancestry
Informative Markers (AIM’s) using the Sequenom iPLEX
assay where two markers failed to give results in all the
individuals, therefore our final analysis was based upon
48 AIM’s. The detailed information about these markers
was published elsewhere [7].
In silico analysis
To evaluate the novel mutations observed exclusively in
the hypertrophic cardiomyopathy (HCM) patients in this
study was the potential cause for the defect in splicing,
we have analyzed those sites with ASD Workbench
wrapper (http://www.ebi.ac.uk/asd-srv/wb.cgi) tools suchas PPT analysis, BP analysis. The regulatory sequence
were used to identify the presence of polypyrimidine
tracks, branch point sites, binding sites for splicing
factors, and exonic splicing enhancers/silencers (ESE/
ESS) or intronic splicing enhancers/silencers (ISE/ISS),
respectively, at the mutation sites. Splicing Rainbow tool
searches for the SR proteins (serine/arginine-rich) as
well as hnRNP motifs were done.
Additional file
Additional file 1: Table S1. Clinical phenotype of the Hypertrophic
Cardiomyopathy Patients.
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